Analysis of Potential Biomarkers in Hypertension
Alexander V. Blagov1*, Margarita A. Sazonova 1,2, Anastasia I. Ryzhkova1, Marina D. Sazonova1, Mikhail A. Popov6, Egor Yu. Budnikov1, Paolo Poggio7, Donato Moschetta7, Yuri V. Arkhipenko1,3, Vasily P. Karagodin5, Alexander N. Orekhov1,4
Integrative Biomedical Research (Former Journal of Angiotherapy) 9(1) 1-12 https://doi.org/10.25163/biomedical.9110267
Submitted: 11 March 2025 Revised: 28 May 2025 Published: 31 May 2025
Abstract
Background: Hypertension is a major global health concern and a leading contributor to cardiovascular and renal diseases. Traditional diagnostic approaches often fail to detect early or atypical forms of hypertension, underscoring the need for sensitive and specific biomarkers to enable timely diagnosis, individualized risk stratification, and improved treatment strategies.
Materials and Methods: This review systematically analyzes both established and emerging biomarkers of hypertension. We evaluated traditional indicators such as renin, aldosterone, natriuretic peptides, and C-reactive protein, alongside recent findings from molecular and omics-based research, including microRNAs, DNA methylation, gut microbiota-derived metabolites, exosomal markers, inflammatory cytokines, and proteomic and metabolomic signatures.
Results: Traditional biomarkers remain essential in diagnosing secondary hypertension but lack specificity and are affected by multiple confounders. Emerging biomarkers demonstrate promising potential for early detection and mechanistic insight. Circulating microRNAs (e.g., miR-21, miR-126), epigenetic modifications (e.g., DNA methylation of CYP11B2), and gut-derived metabolites (e.g., TMAO, SCFAs) are linked to vascular dysfunction, inflammation, and salt sensitivity. Proteomic markers such as ANGPTL3 and MMP-9, along with metabolomic profiles involving BCAAs and oxylipins, correlate with hypertensive phenotypes. Exosomal RNAs and cytokines (e.g., IL-6, TNF-α) further reflect immune and endothelial activity. Multi-omics integration and machine learning approaches are increasingly used to refine biomarker panels for clinical application.
Conclusion: Novel biomarkers provide deeper insight into hypertension pathophysiology and offer opportunities for personalized diagnosis and therapy. However, clinical translation requires validation in large cohorts and standardization of analytical methods. Continued integration of omics technologies will be essential for the future of hypertension management.
Keywords: inflammation, biomarkers, hypertension, vascular, CRP
References
Bakris, G. L., & Ritz, E. (2009). The message for World Kidney Day 2009: Hypertension and kidney disease: A marriage that should be prevented. Kidney International, 75(8), 709–712. https://doi.org/10.1038/ki.2009.43
Bautista, L. E., Vera, L. M., Arenas, I. A., & Gamarra, G. (2005). Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. Journal of Human Hypertension, 19(2), 149–154. https://doi.org/10.1038/sj.jhh.1001799
Bidani, A. K., & Griffin, K. A. (2004). Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension, 44(5), 595–601. https://doi.org/10.1161/01.HYP.0000145850.28481.64
Boutouyrie, P., Tropeano, A. I., Asmar, R., Gautier, I., Benetos, A., Lacolley, P., & Laurent, S. (2002). Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension, 39(1), 10–15. https://doi.org/10.1161/hy0102.099031
Brown, J. M., Siddiqui, M., Calhoun, D. A., Carey, R. M., Hopkins, P. N., Williams, G. H., & Vaidya, A. (2013). The renin-angiotensin-aldosterone system in the pathogenesis and treatment of hypertension. Nature Reviews Nephrology, 9(10), 539–553. https://doi.org/10.1038/nrneph.2013.141
Brown, N. J. (2008). Aldosterone and vascular inflammation. Hypertension, 51(2), 161–167. https://doi.org/10.1161/HYPERTENSIONAHA.107.093401
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison Himmelfarb, C. R., ... & Whelton, P. K. (2017). Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension, 72(5), e53–e90. https://doi.org/10.1161/HYP.0000000000000084
Chen, Y., et al. (2022). Frontiers in Cell and Developmental Biology, 10, 913784. https://doi.org/10.3389/fcell.2022.913784
Cheng, X., et al. (2021). Hypertension Research, 44(3), 245–253. https://doi.org/10.1038/s41440-020-00585-3
Crowley, S. D., & Coffman, T. M. (2012). Recent advances involving the renin–angiotensin system. Hypertension, 60(2), 588–596. https://doi.org/10.1161/HYPERTENSIONAHA.111.189829
De Miguel, C., Guo, C., & Lund, H. (2015). Inflammation and hypertension: New understandings and potential therapeutic targets. Current Hypertension Reports, 17(1), 507. https://doi.org/10.1007/s11906-014-0507-4
El-Missiry, M. A., et al. (2007). Oxidative stress and circulating DNA as biomarkers in hypertension. Clinica Chimica Acta, 383(1–2), 58–64. https://doi.org/10.1016/j.cca.2007.05.012
Esler, M., Lambert, E., & Schlaich, M. (2010). Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. The Journal of Applied Physiology, 109(6), 1996–1998. https://doi.org/10.1152/japplphysiol.00491.2010
Franzén, O., Ermel, R., Cohain, A., Akers, N. K., Di Narzo, A., Talukdar, H. A., ... & Björkegren, J. L. M. (2021). Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science, 353(6301), 827–830. https://doi.org/10.1126/science.aad6970
Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., ... & Young, W. F. (2016). The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 101(5), 1889–1916. https://doi.org/10.1210/jc.2015-4061
GBD 2019 Risk Factors Collaborators. (2020). Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396(10258), 1223–1249. https://doi.org/10.1016/S0140-6736(20)30752-2
Gerstein, H. C., et al. (2001). Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. JAMA, 286(4), 421–426. https://doi.org/10.1001/jama.286.4.421
Ghiadoni, L., et al. (2012). Endothelial function and hypertension. Journal of Hypertension, 30(3), 453–461. https://doi.org/10.1097/HJH.0b013e32834f0e2c
Guzik, T. J., et al. (2007). T cells and vascular inflammation in hypertension. Nature Clinical Practice Cardiovascular Medicine, 4(11), 616–623. https://doi.org/10.1038/ncpcardio1035
Hall, J. E., et al. (1999). Pressure–natriuresis relationship and salt sensitivity of blood pressure in hypertension. Hypertension, 33(3), 912–917. https://doi.org/10.1161/01.HYP.33.3.912
Harrison, D. G., & Gongora, M. C. (2009). Oxidative stress and hypertension. Medical Clinics of North America, 93(3), 621–635. https://doi.org/10.1016/j.mcna.2009.02.007
Harrison, D. G., et al. (2011). Inflammation, immunity, and hypertension. Hypertension, 57(2), 132–140. https://doi.org/10.1161/HYPERTENSIONAHA.110.163576
Ho, J. E., et al. (2021). Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure. JACC: Heart Failure, 9(2), 115–123. https://doi.org/10.1016/j.jchf.2020.10.008
Iadecola, C., & Davisson, R. L. (2008). Hypertension and cerebrovascular dysfunction. Cell Metabolism, 7(6), 476–484. https://doi.org/10.1016/j.cmet.2008.03.010
Intengan, H. D., & Schiffrin, E. L. (2001). Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension, 38(3), 581–587. https://doi.org/10.1161/hy09t1.093959
Itani, H. A., Xiao, L., Saleh, M. A., Wu, J., Pilkinton, M. A., Dale, B. L., ... & Harrison, D. G. (2020). CD70 exacerbates blood pressure elevation and renal damage in response to repeated hypertensive stimuli. Hypertension, 75(2), 466–476. https://doi.org/10.1161/HYPERTENSIONAHA.119.13461
Jhund, P. S., et al. (2009). N-terminal pro-BNP testing in primary care: Impact on heart failure diagnosis and mortality. European Heart Journal, 30(7), 857–866. https://doi.org/10.1093/eurheartj/ehn623
Jiang, L., et al. (2023). A multi-omics approach identifies novel predictors of hypertension progression. Nature Communications, 14, 2231. https://doi.org/10.1038/s41467-023-37427-z
Kobori, H., et al. (2007). The intrarenal renin–angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacological Reviews, 59(3), 251–287. https://doi.org/10.1124/pr.59.3.3
Kontaraki, J. E., et al. (2021). MicroRNA-21 and microRNA-155 are associated with resistant hypertension and inflammation. Journal of Human Hypertension, 35(1), 13–20. https://doi.org/10.1038/s41371-020-0356-3
Kucera, J., et al. (2021). Plasma 8-isoprostane and hypertension: Clinical implications of oxidative stress markers. Free Radical Biology and Medicine, 164, 267–275. https://doi.org/10.1016/j.freeradbiomed.2021.01.009
Laurent, S., et al. (2006). Expert consensus document on arterial stiffness: methodological issues and clinical applications. European Heart Journal, 27(21), 2588–2605. https://doi.org/10.1093/eurheartj/ehl254
Lee, H., Zhang, D., & Wu, J. (2020). Exosomal miRNAs in hypertension: Diagnostic and therapeutic opportunities. Hypertension Research, 43(8), 681–689. https://doi.org/10.1038/s41440-020-0435-8
Levey, A. S., et al. (2009). A new equation to estimate glomerular filtration rate. Annals of Internal Medicine, 150(9), 604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
Lewington, S., et al. (2002). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet, 360(9349), 1903–1913. https://doi.org/10.1016/S0140-6736(02)11911-8
Li, J., et al. (2021). Gut microbiota-derived TMAO: A novel biomarker for hypertension. Hypertension Research, 44(5), 669–678. https://doi.org/10.1038/s41440-020-00579-1
Liu, L., et al. (2022). Metabolomics reveals branched-chain amino acid pathways associated with hypertension development. Circulation Research, 131(3), 250–262. https://doi.org/10.1161/CIRCRESAHA.122.320121
Lu, Y., et al. (2023). miRNA profiling in resistant hypertension: Insight into diagnostic and therapeutic biomarkers. Hypertension Research, 46(2), 256–265. https://doi.org/10.1038/s41440-022-00999-8
Ma, J., et al. (2023). Trimethylamine-N-oxide contributes to salt-sensitive hypertension via endothelial dysfunction. Hypertension, 80(2), 380–392. https://doi.org/10.1161/HYPERTENSIONAHA.122.20367
Maisel, A. S., et al. (2002). Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New England Journal of Medicine, 347(3), 161–167. https://doi.org/10.1056/NEJMoa020233
McKie, P. M., et al. (2010). NT-proBNP and the prediction of new-onset hypertension. Hypertension, 56(4), 623–630. https://doi.org/10.1161/HYPERTENSIONAHA.110.156851
Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., ... & He, J. (2016). Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation, 134(6), 441–450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912
Mitchell, G. F., et al. (2010). Arterial stiffness and cardiovascular events. New England Journal of Medicine, 362(10), 917–927. https://doi.org/10.1056/NEJMoa090756
Muntner, P., Shimbo, D., Carey, R. M., Charleston, J. B., Gaillard, T., Misra, S., ... & Wright, J. T. (2019). Measurement of blood pressure in humans: A scientific statement from the American Heart Association. Hypertension, 73(5), e35–e66. https://doi.org/10.1161/HYP.0000000000000087
Norlander, A. E., Madhur, M. S., & Harrison, D. G. (2022). The immune system in hypertension. Current Hypertension Reports, 24(2), 1–11. https://doi.org/10.1007/s11906-022-01176-8
Oparil, S., et al. (2003). Pathogenesis of hypertension. Annals of Internal Medicine, 139(9), 761–776. https://doi.org/10.7326/0003-4819-139-9-200311040-00011
Paulus, W. J., & Tschöpe, C. (2013). A novel paradigm for heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 62(4), 263–271. https://doi.org/10.1016/j.jacc.2013.02.092
Pérez-Gómez, M. V., Ortiz, A., & Morales, E. (2022). Biomarkers in arterial hypertension: New insights and clinical implications. Current Hypertension Reports, 24(5), 163–175. https://doi.org/10.1007/s11906-022-01159-9
Pluznick, J. L., et al. (2020). Short-chain fatty acid signaling and blood pressure regulation. Physiological Reviews, 100(4), 1727–1774. https://doi.org/10.1152/physrev.00032.2019
Rangel, I. C., et al. (2019). Epigenetic regulation in arterial hypertension. International Journal of Molecular Sciences, 20(15), 3828. https://doi.org/10.3390/ijms20153828
Richard, M. A., et al. (2021). DNA methylation loci associated with blood pressure and hypertension. Nature Communications, 12(1), 1–14. https://doi.org/10.1038/s41467-021-21313-6
Sesso, H. D., Buring, J. E., Rifai, N., Blake, G. J., Gaziano, J. M., & Ridker, P. M. (2003). C-reactive protein and the risk of developing hypertension. JAMA, 290(22), 2945–2951. https://doi.org/10.1001/jama.290.22.2945
Sun, Y., et al. (2021). Proteomic profiling in hypertension: Identification of early-stage biomarkers. Journal of Proteome Research, 20(4), 2030–2041. https://doi.org/10.1021/acs.jproteome.0c00960
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., ... & Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13–e115. https://doi.org/10.1161/HYP.0000000000000065
World Health Organization. (2023). Hypertension. https://www.who.int/news-room/fact-sheets/detail/hypertension
Xu, Y., et al. (2022). Global DNA hypomethylation is associated with increased blood pressure in adults: A meta-analysis. Epigenetics, 17(5), 511–521. https://doi.org/10.1080/15592294.2022.2046655
Yan, Q., et al. (2022). Gut microbiota dysbiosis contributes to hypertension via SCFA-mediated GPR41 signaling. Nature Reviews Nephrology, 18(2), 77–89. https://doi.org/10.1038/s41581-021-00522-7
Yazdani, S., et al. (2021). MicroRNAs as biomarkers in hypertension: A systematic review. Journal of the Renin-Angiotensin-Aldosterone System, 22, 1–10. https://doi.org/10.1177/14703203211026044
Young, W. F. (2007). Primary aldosteronism: Renaissance of a syndrome. Clinical Endocrinology, 66(5), 607–618. https://doi.org/10.1111/j.1365-2265.2007.02899.x
Yuyun, M. F., et al. (2004). Microalbuminuria predicts cardiovascular mortality independently of conventional risk factors in a middle-aged cohort. Journal of the American Society of Nephrology, 15(6), 1834–1841. https://doi.org/10.1097/01.ASN.0000126466.18372.6B
Zhang, Y., et al. (2021). LINE-1 hypomethylation and hypertension: A meta-analysis of EWAS studies. Hypertension, 77(4), 1109–1118. https://doi.org/10.1161/HYPERTENSIONAHA.120.16517
Zhang, Y., et al. (2022). Associations of omega-3/6-derived oxylipins with blood pressure regulation in humans. Hypertension, 79(1), 120–130. https://doi.org/10.1161/HYPERTENSIONAHA.121.18374
Zhao, Y., Zhang, X., Zhang, J., Sun, Y., & Zhao, L. (2022). LncRNA-Ang362 promotes hypertension by enhancing vascular smooth muscle cell proliferation. Molecular Therapy – Nucleic Acids, 28, 208–219. https://doi.org/10.1016/j.omtn.2022.07.015
Zheng, Y., et al. (2021). Metabolomics of hypertension and risk of cardiovascular disease: The role of branched-chain amino acids. Hypertension, 77(3), 761–770. https://doi.org/10.1161/HYPERTENSIONAHA.120.16158
Zhou, X., et al. (2022). Exosomal miRNAs as early diagnostic biomarkers for essential hypertension. Hypertension Research, 45(6), 1002–1011. https://doi.org/10.1038/s41440-022-00859-5
View Dimensions
View Altmetric
Save
Citation
View
Share